Chronic Low Back Pain Market an Attractive Commercial Opportunity for Drug Developers Because of Large Drug-Treated Population

Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the chronic low back pain (CLBP) market continues to be an attractive commercial opportunity because of the large drug-treated population. According to the now available report entitled Chronic Low Back Pain -- Large Drug-Treated Population, High Unmet Need but Pricing Concerns Restrain Growth, more than 15 million CLBP sufferers in the major pharmaceutical markets will receive a prescription drug for CLBP in 2009, making the drug-treated population among the largest markets served by the pharmaceutical industry.

"Although attractive to drug development because of its large patient population and high need for more effective agents, the pricing potential for emerging therapies may be a deterrent to the development of novel therapies," said Michelle Grady, Therapeutic Area Director at Decision Resources. "Compared with other disease markets, the back pain market is relatively price-constrained; even in the robust U.S. pharmaceutical market."

About Chronic Low Back Pain -- Large Drug-Treated Population, High Unmet Need but Pricing Concerns Restrain Growth

Chronic Low Back Pain -- Large Drug-Treated Population, High Unmet Need but Pricing Concerns Restrain Growth covers the current state of the chronic low back pain drug market. The report includes the following:

  * Analysis of the chronic low back pain market that focuses on the     diagnosed/drug treated populations, patient/market share projections,     cost-per-day and compliance expectations   * Opportunity (dollar and market share) for a drug that would have a     better safety profile then the COX2s and a better efficacy score on the     RMDQ   * Current pricing environment discussions by market that identify the     physician's current treatment approach and how this is guided by     regulatory and pricing concerns.   * 10-year market forecast projecting the impact of emerging therapies  

The report can be purchased by contacting Decision Resources. Members of the media may request a complimentary copy.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources, Inc.